HBK Investments’s Pfizer PFE Stock Holding History

HBK Investments’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,500	Closed	-$856K	–	355
2026 Q1	$856K	Buy	+30,500	New	+$812K	0.01%	273
2023 Q3	–	Sell	-9,400	Closed	-$345K	–	404
2023 Q2	$345K	Sell	9,400 -74,500	-89%	-$2.9M	﹤0.01%	348
2023 Q1	$3.42M	Buy	+83,900	New	+$3.62M	0.02%	119
2022 Q4	–	Sell	-71,200	Closed	-$3.12M	–	166
2022 Q3	$3.12M	Sell	71,200 -162,000	-69%	-$7.87M	0.02%	258
2022 Q2	$12.2M	Buy	233,200 +174,800	+299%	+$8.91M	0.07%	87
2022 Q1	$3.02M	Buy	+58,400	New	+$3.03M	0.01%	361
2021 Q3	–	Sell	-232,700	Closed	-$9.11M	–	860
2021 Q2	$9.11M	Buy	232,700 +159,400	+217%	+$6.2M	0.03%	136
2021 Q1	$2.66M	Buy	+73,300	New	+$2.6M	0.01%	424
2020 Q1	–	Sell	-16,864	Closed	-$627K	–	396
2019 Q4	$627K	Sell	16,864 -86,006	-84%	-$3.06M	0.01%	552
2019 Q3	$3.51M	Sell	102,870 -11,805	-10%	-$429K	0.04%	332
2019 Q2	$4.71M	Sell	114,675 -151,882	-57%	-$6.03M	0.04%	246
2019 Q1	$10.7M	Buy	+266,557	New	+$10.7M	0.11%	154

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HBK Investments's PFE Position: Q2 2026 in Review

HBK Investments sold out of Pfizer (PFE) in Q2 2026, closing a stake of 10,878 shares — an estimated $305K sold.

HBK Investments first reported a position in PFE in Q4 2015 and held it in 8 quarters. The position peaked at $33.6M in Q1 2019. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

HBK Investments reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
HBK Investments sold 10,878 Pfizer shares in Q2 2026, an estimated $305K.
HBK Investments first reported a position in Pfizer in Q4 2015 and held it in 8 quarters.
HBK Investments's Pfizer position peaked at $33.6M in Q1 2019.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on HBK Investments's 13F filing for Q2 2026, filed 14 Aug 2026.